AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Lakewood-Amedex Biotherapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG01ZK61CF1
0.31▼ 0.18 (-36.67%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.49
Day's Range
0.28 – 0.36
52-Week Range
0.28 – 9.82
Volume
38.5M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2026-04-23
Share count as of August 3, 2026

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's Market Cap?
Lakewood-Amedex Biotherapeutics Inc. Common Stock's Market Cap is $734.6K, based on as-reported figures from SEC (XBRL) filings.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's Enterprise Value?
Lakewood-Amedex Biotherapeutics Inc. Common Stock's Enterprise Value is $722.9K, based on as-reported figures from SEC (XBRL) filings.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's Net Debt?
Lakewood-Amedex Biotherapeutics Inc. Common Stock's Net Debt is -$11.7K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LABTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Operating expenses:
Research and development
General and administrative
Depreciation
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other income
Total other income (expense), net
Net loss
Basic net loss per common share (in Dollars per share)—
Diluted net loss per common share (in Dollars per share)—